This Is MS Multiple Sclerosis Knowledge & Support Community

Study shows third course of Lemtrada improves MS patient’s relapse rate and disability A study released at #ACTRIMS2018 has revealed that patients who experienced relapses after two courses of Lemtrada (alemtuzumab) showed improvement in relapse rate and disability progression after a third course o...

Germany recently informed the European Medicines Agency (EMA) that seven patients with multiple sclerosis (MS) had developed immune-mediated inflammation of the brain (encephalitis) during treatment with daclizumab beta (Zinbryta). Three of these patients also had a severe allergic reaction (drug re...

Eating fish at least once a week or eating fish one to three times per month in addition to taking daily fish oil supplements may be associated with a reduced risk of multiple sclerosis (MS), according to a preliminary study released that will be presented at the American Academy of Neurology's 70th...

Progress on the legalisation of medical cannabis takes a side step On Friday 23 February, the United Patients Alliance gathered for another peaceful protest outside the House of Parliament while the second reading of the Emily Brice bill took place…Read more - http://www.ms-uk.org/progress-legalisat...

Study highlights 93.7% improvement in patients treated with cannabis In recent years there has been a substantial increase in the use of medical cannabis, particularly with the aging population. In a recent study, titled “Epidemiological characteristics, safety and efficacy of medical cannabis in th...

Study reveals the risks associated between MS drug natalizumab and pregnancy A recent study, published in the journal Neurology, assessed foetal risk after pregnancy exposure to natalizumab (Tysabri) in women with multiple sclerosis (MS). The Italian study specifically focused on spontaneous abortio...

Sandoz, a Novartis division, has announced US Food and Drug Administration (FDA) approval and launched a 40 mg/ml dose of Glatopa, a glatiramer acetate injection…Read more - http://www.ms-uk.org/higher-dose-ms-drug-glatopa-finally-gets-us-approval https://scontent-lht6-1.xx.fbcdn.net/v/t1.0-9/261688...

NHS Scotland has accepted cladribine (Mavenclad) as a treatment option for people with highly active multiple sclerosis (MS) living in Scotland… http://www.ms-uk.org/cladribine-gets-approval-scotland https://scontent-lht6-1.xx.fbcdn.net/v/t1.0-9/26168845_1680181818687432_2707888596679484414_n.png?oh...

Experimental therapy restores nerve insulation damage caused by autoimmune conditions When the body attacks its own healthy tissues in an autoimmune condition, peripheral nerve damage disable people and causes persistent neuropathic pain when insulation on healing nerves doesn't fully regenerate…Rea...

Changing natalizumab dosing frequency reduced risk for Progressive Multifocal Leukoencephalopathy (PML) A commonly-prescribed multiple sclerosis (MS) infusion medication linked to a rare but serious side effect is safer to use when dosing intervals are extended, according to a new study led by MS sp...

Survey Highlights Misconceptions about Family Planning among Women with Relapsing Forms of Multiple Sclerosis Of 1,000 women diagnosed with relapsing remitting multiple sclerosis (RRMS) in the last five years, 88% were concerned they would not be able to have children, despite studies that show othe...

MS drug ibudilast demonstrated a 26% reduction in confirmed disability progression in progressive MS trial Biopharmaceutical Company MediciNova has announced additional positive clinical data from its SPRINT-MS phase IIB trial of MN-166 (ibudilast) in progressive multiple sclerosis (PMS)...Read more...

According to a study, published in the 31 January 2018 online edition of Neurology, the medical journal of the American Academy of Neurology, a special programme of balance and eye movement exercises may help people with multiple sclerosis (MS)... Read more - http://www.ms-uk.org/balance-and-eye-mov...

The Dutch Medicines Evaluation Board has signed off AXIM Biotechnologies’ MedChew Rx clinical development programme, which will see them develop and trial a cannabis based chewing gum…Read more - http://www.ms-uk.org/holland-approves-cannabis-chewing-gum-development-programme https://scontent-lht6-1...

Gilenya withdrawal may trigger the return of pre-treatment disease activity It is difficult to identify patients at risk of disease reactivation. So in a recent study scientists at Cerrahpasa School of Medicine, Istanbul University in Turkey compared the demographic and clinical features of patients...